Tag: GlobeNewswire

Plesio and the Zouari Family finalize the strengthening of their partnership

Plesio and the Zouari Family announce the closing of the operation announced on 8 June 2026¹, aimed at strengthening their historic partnership of more than 25 years.

In this context:

• The structure dedicated to the development of the Franprix network is now organized around a capital partnership between the Zouari Family, with a c.60% stake, and Franprix, with a c.40% stake;
• In parallel, Franprix now owns the entire Pro Distribution structure, which was previously 73% owned, and which operates around 90 stores.

The closing of this partnership operation offers an organization more legible, more agile and better-adapted to the network’s development ambitions.

ABOUT PLESIO

PLESIO is France leading convenience retail network, with nearly 25,000 employees, c.6,500 stores and €12.5 billion in business volume in 2025. With a history spanning more than 125 years, the Group brings together seven brands: Monoprix, Casino, Spar, Vival, Cdiscount, Franprix and Naturalia. It is growing across three key markets: daily food shopping, quick meal solutions and new everyday services, with one mission: to serve customers well, in store and online, by adapting its offering to people’s lifestyles and the needs of each local community. Casino, Guichard-Perrachon S.A., the parent company of the Group, is listed on Euronext Paris (ISIN: FR001400OKR3).

---

¹ Press release dated 8 June 2026

Attachment

• PR PLESIO Closing Plesio Zouari partnership operation_2 November 2026

Plesio and the Zouari Family finalize the strengthening of their partnership

Plesio and the Zouari Family announce the closing of the operation announced on 8 June 2026¹, aimed at strengthening their historic partnership of more than 25 years.

In this context:

• The structure dedicated to the development of the Franprix network is now organized around a capital partnership between the Zouari Family, with a c.60% stake, and Franprix, with a c.40% stake;
• In parallel, Franprix now owns the entire Pro Distribution structure, which was previously 73% owned, and which operates around 90 stores.

The closing of this partnership operation offers an organization more legible, more agile and better-adapted to the network’s development ambitions.

ABOUT PLESIO

PLESIO is France leading convenience retail network, with nearly 25,000 employees, c.6,500 stores and €12.5 billion in business volume in 2025. With a history spanning more than 125 years, the Group brings together seven brands: Monoprix, Casino, Spar, Vival, Cdiscount, Franprix and Naturalia. It is growing across three key markets: daily food shopping, quick meal solutions and new everyday services, with one mission: to serve customers well, in store and online, by adapting its offering to people’s lifestyles and the needs of each local community. Casino, Guichard-Perrachon S.A., the parent company of the Group, is listed on Euronext Paris (ISIN: FR001400OKR3).

---

¹ Press release dated 8 June 2026

Attachment

• PR PLESIO Closing Plesio Zouari partnership operation_2 November 2026

Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications

Aaron Tansy, M.D., appointed as Vice President, Development Franchise Head, Neurology, brings complementary expertise in neurology and global clinical development

ZUG, Switzerland, November 2, 2026 — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations in neuro-ophthalmology and ophthalmology, today announced the appointment of Björn Tackenberg, M.D., Ph.D., FEAN, FAAN and Professor of Neurology as its new Chief Scientific Officer (CSO). Prof. Tackenberg will lead Oculis’ global integrated scientific strategy, research portfolio development and value creation, expansion into novel drug candidates, and related strategic scientific partnerships and external engagements. His initial priorities will focus on advancing Oculis’ lead asset Privosegtor through the PIONEER registrational program and evaluating its therapeutic potential in acute multiple sclerosis (MS) relapses and additional neurological indications.

Prof. Tackenberg joins Oculis from Roche, where he served as Head of Integrative Neuroscience & Medical Practice, encompassing clinical development plans and study design, biomarker development and evidence-generation strategies, and strategic partnerships with academic and scientific institutions. Previously, he served as Head of the Center of Neuroimmunology and Vice-Chair of the Department of Neurology at Marburg University in Germany from 2008 to 2019. During his tenure, he established a clinical trials unit that conducted more than 75 randomized controlled trials in autoimmune indications and a tertiary reference center for complex autoimmune treatments. As an experienced and successful industry leader, board-certified neurologist and physician-scientist, Prof. Tackenberg brings deep clinical and scientific expertise in MS, neuroimmunology, neurodegenerative and neuromuscular diseases. He has authored or co-authored over 135 original publications, as well as treatment guidelines for MS, myasthenia gravis and inflammatory neuropathies. His career bridges basic neuroscience and academic clinical neurology, translational research, pharmaceutical and biomarker development, and scientific and medical affairs. Prof. Tackenberg is a Fellow of both the European Academy of Neurology and the American Academy of Neurology.

Riad Sherif, M.D., Chief Executive Officer of Oculis, said: “Oculis is building a world-leading neuro-ophthalmology and neurology franchise. We are exceptionally pleased to welcome Björn as Chief Scientific Officer and Aaron as Development Franchise Head, Neurology, as we advance Privosegtor through the PIONEER registrational program, and prepare to explore its potential in acute MS relapses and other neurological indications. Björn and Aaron bring highly complementary leadership across scientific strategy, development execution, and translational advancement. Their collective experience in neurology, neuroimmunology, neuromuscular and neurodegenerative diseases spanning academic research, clinical practice and pharmaceutical development will materially strengthen Oculis’ ability to translate emerging insights into new therapeutic opportunities.”

Björn Tackenberg, M.D., Chief Scientific Officer of Oculis, added: “I am excited to join Oculis at this pivotal time in the Company’s growth. Privosegtor is a highly promising innovation with the potential to advance neuroprotection, and the opportunity to help shape its development is invaluable. Building on the PIONEER program in neuro-ophthalmology, I look forward to working with the Oculis team and external scientific partners to explore Privosegtor’s potential in acute MS relapses and other neurological indications, translate research into meaningful evidence for patients, and evaluate new opportunities to address significant unmet needs for people living with neurological conditions.”

Aaron Tansy, M.D., recently joined Oculis as Vice President, Development Franchise Head, Neurology. A board-certified neurologist, Dr. Tansy brings clinical research and drug development experience spanning early-stage studies through commercial approval, including programs in MS, amyotrophic lateral sclerosis (ALS), autoimmune disorders and rare diseases. His experience includes global clinical development planning, Phase 1–3 trial design and execution, medical and safety oversight, and interactions with U.S. and European regulatory authorities from investigational applications through marketing submissions. He most recently served as Executive Medical Director, Clinical Development at PTC Therapeutics and previously held clinical development roles at Ovid Therapeutics and Teva Pharmaceutical Industries.

– Ends –

About Privosegtor 

Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improved visual function, corroborated by anatomical preservation of the retina, including the GCIPL and RNFL layers, and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Consistent results were observed in animal models of glaucoma, optic neuritis and multiple sclerosis, where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility in the multiple sclerosis model. 

Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and Priority Medicines (PRIME) designation from the European Medicines Agency, as well as Orphan Drug designation from both agencies for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy. 

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country. 

About Oculis 

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial and is being developed with a genotype-based approach for treating patients with dry eye disease. Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. 

For more information, please visit: www.oculis.com 

Contacts 

Oculis Contact 
Ms. Sylvia Cheung, CFO 
sylvia.cheung@oculis.com 

Investor Relations 
LifeSci Advisors 
Corey Davis, Ph.D. 
cdavis@lifesciadvisors.com 

Media Relations 
ICR Healthcare 
Amber Fennell / David Daley / Sean Leous 
oculis@icrhealthcare.com 

Cautionary Statement Regarding Forward-Looking Statements 

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotective therapy for optic neuritis and other neuro-ophthalmic and neuro-axonal diseases and the potential for Licaminlimab to transform the treatment paradigm in dry eye disease with a precision medicine approach; the initiation, enrollment, timing, progress and results of current and future clinical trials; Oculis’ research and development programs, regulatory and business strategy; and Oculis’ future development plans, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and subject to risks, variability and contingencies, many of which are beyond Oculis’ control. Results from prior clinical trials may not be replicated in later clinical trials. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those expected and/or expressed or implied by such forward-looking statements, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. 

Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications

Aaron Tansy, M.D., appointed as Vice President, Development Franchise Head, Neurology, brings complementary expertise in neurology and global clinical development

ZUG, Switzerland, November 2, 2026 — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations in neuro-ophthalmology and ophthalmology, today announced the appointment of Björn Tackenberg, M.D., Ph.D., FEAN, FAAN and Professor of Neurology as its new Chief Scientific Officer (CSO). Prof. Tackenberg will lead Oculis’ global integrated scientific strategy, research portfolio development and value creation, expansion into novel drug candidates, and related strategic scientific partnerships and external engagements. His initial priorities will focus on advancing Oculis’ lead asset Privosegtor through the PIONEER registrational program and evaluating its therapeutic potential in acute multiple sclerosis (MS) relapses and additional neurological indications.

Prof. Tackenberg joins Oculis from Roche, where he served as Head of Integrative Neuroscience & Medical Practice, encompassing clinical development plans and study design, biomarker development and evidence-generation strategies, and strategic partnerships with academic and scientific institutions. Previously, he served as Head of the Center of Neuroimmunology and Vice-Chair of the Department of Neurology at Marburg University in Germany from 2008 to 2019. During his tenure, he established a clinical trials unit that conducted more than 75 randomized controlled trials in autoimmune indications and a tertiary reference center for complex autoimmune treatments. As an experienced and successful industry leader, board-certified neurologist and physician-scientist, Prof. Tackenberg brings deep clinical and scientific expertise in MS, neuroimmunology, neurodegenerative and neuromuscular diseases. He has authored or co-authored over 135 original publications, as well as treatment guidelines for MS, myasthenia gravis and inflammatory neuropathies. His career bridges basic neuroscience and academic clinical neurology, translational research, pharmaceutical and biomarker development, and scientific and medical affairs. Prof. Tackenberg is a Fellow of both the European Academy of Neurology and the American Academy of Neurology.

Riad Sherif, M.D., Chief Executive Officer of Oculis, said: “Oculis is building a world-leading neuro-ophthalmology and neurology franchise. We are exceptionally pleased to welcome Björn as Chief Scientific Officer and Aaron as Development Franchise Head, Neurology, as we advance Privosegtor through the PIONEER registrational program, and prepare to explore its potential in acute MS relapses and other neurological indications. Björn and Aaron bring highly complementary leadership across scientific strategy, development execution, and translational advancement. Their collective experience in neurology, neuroimmunology, neuromuscular and neurodegenerative diseases spanning academic research, clinical practice and pharmaceutical development will materially strengthen Oculis’ ability to translate emerging insights into new therapeutic opportunities.”

Björn Tackenberg, M.D., Chief Scientific Officer of Oculis, added: “I am excited to join Oculis at this pivotal time in the Company’s growth. Privosegtor is a highly promising innovation with the potential to advance neuroprotection, and the opportunity to help shape its development is invaluable. Building on the PIONEER program in neuro-ophthalmology, I look forward to working with the Oculis team and external scientific partners to explore Privosegtor’s potential in acute MS relapses and other neurological indications, translate research into meaningful evidence for patients, and evaluate new opportunities to address significant unmet needs for people living with neurological conditions.”

Aaron Tansy, M.D., recently joined Oculis as Vice President, Development Franchise Head, Neurology. A board-certified neurologist, Dr. Tansy brings clinical research and drug development experience spanning early-stage studies through commercial approval, including programs in MS, amyotrophic lateral sclerosis (ALS), autoimmune disorders and rare diseases. His experience includes global clinical development planning, Phase 1–3 trial design and execution, medical and safety oversight, and interactions with U.S. and European regulatory authorities from investigational applications through marketing submissions. He most recently served as Executive Medical Director, Clinical Development at PTC Therapeutics and previously held clinical development roles at Ovid Therapeutics and Teva Pharmaceutical Industries.

– Ends –

About Privosegtor 

Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improved visual function, corroborated by anatomical preservation of the retina, including the GCIPL and RNFL layers, and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Consistent results were observed in animal models of glaucoma, optic neuritis and multiple sclerosis, where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility in the multiple sclerosis model. 

Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and Priority Medicines (PRIME) designation from the European Medicines Agency, as well as Orphan Drug designation from both agencies for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy. 

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country. 

About Oculis 

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial and is being developed with a genotype-based approach for treating patients with dry eye disease. Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. 

For more information, please visit: www.oculis.com 

Contacts 

Oculis Contact 
Ms. Sylvia Cheung, CFO 
sylvia.cheung@oculis.com 

Investor Relations 
LifeSci Advisors 
Corey Davis, Ph.D. 
cdavis@lifesciadvisors.com 

Media Relations 
ICR Healthcare 
Amber Fennell / David Daley / Sean Leous 
oculis@icrhealthcare.com 

Cautionary Statement Regarding Forward-Looking Statements 

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotective therapy for optic neuritis and other neuro-ophthalmic and neuro-axonal diseases and the potential for Licaminlimab to transform the treatment paradigm in dry eye disease with a precision medicine approach; the initiation, enrollment, timing, progress and results of current and future clinical trials; Oculis’ research and development programs, regulatory and business strategy; and Oculis’ future development plans, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and subject to risks, variability and contingencies, many of which are beyond Oculis’ control. Results from prior clinical trials may not be replicated in later clinical trials. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those expected and/or expressed or implied by such forward-looking statements, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. 

Infortar will arrange a webinar for investors today 2 November 2026. Please join the webinar via the following links:

at 12:00 (Tallinn local time) Estonian webinar
at 14:00 (Tallinn local time) English webinar

At the end of September, Infortar’s total assets stood at €2.62 billion and equity at €1.25 billion. The Group’s borrowings decreased by 5.5% compared with the end of the previous year to €1.01 billion, while net debt declined by 2.8% to €828 million. In the third quarter, Infortar generated revenue of €458 million and a net profit of €50 million.

“The third quarter brought key decisions that will shape Infortar’s development in the years ahead and create a platform for further growth. We have consistently expanded our operations in sectors where we see long-term growth potential. In September, we signed an agreement to acquire the Lithuanian agricultural group Litagra at an enterprise value of €95 million. We completed the acquisition in October, making Infortar Agro the largest milk producer in the Baltic states. This marks an important step in the development of our agricultural business and provides a strong foundation for further growth,” said Ain Hanschmidt, Chairman of the Management Board of Infortar.

“Tallink delivered a strong summer quarter, with growth in passenger numbers, cargo volumes and revenue. Despite rising fuel prices and environmental levies, Tallink remains focused on cost efficiency. Elenger focused on ensuring a reliable supply of energy for its customers ahead of the heating season, increasing its gas storage inventories and securing additional LNG deliveries. Our real estate business continued to grow steadily and rental income increased,” Hanschmidt added.

Major Events
Energy

In the third quarter, natural gas consumption in the Baltic-Finnish region totalled 5.6 TWh, decreasing by 6% compared with the previous year (5.9 TWh). Elenger Grupp’s gas and electricity sales volumes in the third quarter decreased by 27% year on year to 2.8 TWh (compared to 3.8 TWh in Q3 2025). The decline was primarily driven by a reduction in wholesale sales. Despite the overall decline in sales volumes, Elenger’s gas market share in the Baltic-Finnish market increased to 31%, and Estonia accounted for 14% of energy sales.

Maritime transport

In the third quarter, Tallink carried 1,816,174 passengers, representing a 2.8% increase year-on-year. The number of cargo units transported increased by 7.8% to 64,980, while the number of passenger vehicles decreased by 1.1% to 249,100.

As at the end of the quarter, Tallink operated 11 vessels including 2 shuttle vessels, 5 passenger vessels, 3 vessels that were chartered out and 1 in lay-up.

Real estate and infrastructure

In Q3 2026, INF Infra, part of the Infortar Group, continued the construction of Rail Baltica’s mainline on the Kangru-Saku section. The contract value is EUR 67.2 million, and the work is planned to continue until March 2028.

In Q3 2026, construction of a Depo DIY Store continued on the property adjacent to the Tallink Tennis Centre. The project is scheduled for completion in the spring of 2027.

In Q3 2026, the reconstruction and expansion project of the Radisti 7 warehouse and office building continued. The works are being carried out by INF Ehitus and are scheduled for completion by the end of 2026.

Key financial figures

Key figures	Q3 2026	Q3 2025	9 months 2026	9 months 2025
Revenue, m€	457.508	467.693	1,403.425	1,419.562
Gross profit, m€	93.849	95.828	207.981	177.564
EBITDA, m€	87.423	104.927	198.651	189.978
EBITDA margin (%)	19.1%	22.4%	14.2%	13.4%
Operating profit (EBIT), m€	66.732	64.836	117.800	91.219
Profit before tax, m€	52.296	73.019	79.491	75.714
Income tax expense, m€	-1.897	-0.780	-21.891	-17.886
Net profit (-loss), m€	50.399	72.239	57.600	57.828
Net profit (-loss) attributable to owners of the parent, m€	43.439	59.068	58.602	56.519
Earnings per share (euros)*	2.11	2.87	2.84	2.75
Total equity, m€	1,248.133	1,207.947	1,248.133	1,207.947
Loan and lease liabilities, m€	1,012.732	1,035.423	1,012.732	1,035.423
Net debt, m€	828.009	899.281	828.009	899.281
Investment loans / EBITDA**	3.0x	3.3x	3.0x	3.3x

_{*Basic earnings per share is calculated by dividing profit attributable to owners of the parent for the period by the weighted average number of ordinary shares outstanding during the same period, excluding own shares.** The investment loans to EBITDA ratio is calculated by dividing long-term investment loans disclosed in Note 7.1 by EBITDA for the trailing twelve months, comprising the first nine months of the reporting year and the fourth quarter of the previous year.}

Revenue

In the first nine months of the 2026 financial year, the Group’s consolidated revenue was EUR 1,403.425 million (9 months 2025: EUR 1,419.562 million).

EBITDA and Segment Reporting

In the first nine months of the 2026 financial year, the maritime transport segment’s EBITDA was EUR 104.025 million (9 months 2025: EUR 102.217 million).

In the first nine months of the 2026 financial year, the energy segment’s EBITDA was EUR 71.476 million (9 months 2025: EUR 76.597 million).

The profitability of the real estate segment is assessed based on the standalone EBITDA of the real estate companies. In the first nine months of the 2026 financial year, real estate EBITDA was EUR 12.034 million (9 months 2025: EUR 10.962 million).

Net Profit (Loss)

In the first nine months of the 2026 financial year, consolidated net profit was EUR 57.600 million, of which EUR 58.602 million was attributable to owners of the parent (9 months 2025: EUR 57.828 million and EUR 56.519 million, respectively).

Investments

In the first nine months of the 2026 financial year, the Group’s total investments amounted to approximately EUR 61 million (9 months 2025: EUR 96 million).

Financing

As at 30 September 2026, loan and lease liabilities totalled EUR 1,012.732 million (31 December 2025: EUR 1,071.353 million).

As at 30 September 2026, the Group’s net debt was EUR 828.009 million (31 December 2025: EUR 851.582 million). The net debt to EBITDA ratio was 3.1 (31 December 2025: 3.7).

Dividends

According to the dividend policy, the objective is to pay dividends of at least 1 euro per share per financial year. Based on Resolution 2.2 of the Annual General Meeting approved on 4 June 2026, a dividend of EUR 3.02 per share will be paid to shareholders for the 2025 financial year. The first payment was made on 15 July 2026, and the second payment will be made on 15 December 2026 with transfer to the shareholders’ bank accounts.

STATEMENT OF FINANCIAL POSITION

(in thousands of EUR)	30.09.26	31.12.25
Current assets
Cash and cash equivalents	184 723	219 771
Derivative financial assets	62 115	4 732
Settled derivative receivables	4 376	1 823
Trade receivables	138 436	153 473
Prepayments for taxes	7 642	5 659
Other receivables and prepayments	45 677	38 878
Prepayments for inventories	1 039	476
Inventories	99 692	90 672
Biological assets	1 471	1 545
Total current assets	545 171	517 029
Non-current assets	30.09.26	31.12.25
Investments in associates	16 339	21 412
Long-term derivative instruments	10 781	1 079
Other non-current receivables	32 892	31 648
Property, plant and equipment at fair value	1 187 384	1 202 173
Investment property	68 629	66 872
Property, plant and equipment	673 344	669 797
Intangible assets	36 864	37 930
Right-of-use assets	41 726	39 645
Biological assets	7 794	9 022
Total non-current assets	2 075 753	2 079 578
TOTAL ASSETS	2 620 924	2 596 607
(in thousands of EUR)	30.09.26	31.12.25
Current liabilities
Loan liabilities	229 556	338 515
Lease liabilities	7 653	10 029
Trade payables	108 555	123 330
Tax liabilities	52 584	44 972
Buyers’ advances	37 053	38 621
Settled derivatives	2 211	4 156
Other current liabilities	79 306	69 677
Short-term derivative instruments	21 411	9 552
Total current liabilities	538 329	638 852
Non-current liabilities	30.09.26	31.12.25
Long-term provisions	6 794	8 695
Deferred tax liabilities	2 183	1 894
Other long-term liabilities	48 399	46 028
Long-term derivatives	1 563	2 925
Loan liabilities	741 627	686 187
Lease liabilities	33 896	36 622
Total non-current liabilities	834 462	782 351
TOTAL LIABILITIES	1 372 791	1 421 203
(in thousands of EUR)	30.09.26	31.12.25
Equity
Share capital	2 117	2 117
Own shares	-3 076	-790
Share premium	32 484	32 484
Reserve capital	212	212
Option reserve	13 663	10 099
Hedging reserve	46 284	-7 260
Unrealised exchange rate differences	-2 461	1 167
Post-employment benefit obligation reserve	-550	-559
Retained earnings	903 763	884 204
Total equity attributable to equity holders of the Parent	992 436	921 674
Non-controlling interests	255 697	253 730
Total equity	1 248 133	1 175 404
TOTAL LIABILITIES AND EQUITY	2 620 924	2 596 607

CONSOLIDATED INCOME STATEMENT

(in thousands of EUR)	Q3 2026	Q3 2025	9 months 2026	9 months 2025
Revenue	457 508	467 693	1 403 425	1 419 562
Cost of goods and services sold	-363 665	-371 837	-1 195 355	-1 241 781
Write-down of receivables	6	-28	-89	-217
Gross profit	93 849	95 828	207 981	177 564
Marketing expenses	-10 458	-11 123	-33 840	-34 218
General administrative expenses	-20 643	-18 804	-65 930	-62 325
Profit (loss) from derivatives	1 291	-1 145	-214	8 037
Profit (loss) from biological assets	2 448	4 511	3 714	4 615
Gain/(loss) from changes in the fair value of non-current assets	0	-5 607	0	-5 607
Other operating income	894	2 237	10 412	6 473
Other operating expenses	-649	-1 061	-4 323	-3 320
Operating profit	66 732	64 836	117 800	91 219
(in thousands of EUR)	Q3 2026	Q3 2025	9 months 2026	9 months 2025
Profit (loss) from investments accounted for using the equity method	292	619	-1 849	1 940
Financial income and expenses:
Income/(expense) from financial investments	-2 365	17 595	-2 583	16 984
Interest expense	-12 050	-10 323	-33 081	-34 800
Interest income	773	609	2 479	2 346
Profit (loss) from changes in exchange rates	-199	388	-1 116	2
Other financial income and expenses	-887	-705	-2 159	-1 977
Total financial income and expenses	-14 728	7 564	-36 460	-17 445
Profit before tax	52 296	73 019	79 491	75 714
Corporate income tax	-1 897	-780	-21 891	-17 886
Profit/(loss) for the period	50 399	72 239	57 600	57 828
including:
Profit attributable to the owners of the parent company	43 439	59 068	58 602	56 519
Profit attributable to non-controlling interests	6 960	13 171	-1 002	1 309

Other comprehensive income	9 months 2026	9 months 2025
Items that will not be reclassified to profit or loss:
Revaluation of post-employment benefit obligations	9	141
Items that may be subsequently reclassified to profit or loss:
Cash flow hedging instruments – effective portion of changes in fair value	53 544	21 096
Exchange rate differences attributable to foreign subsidiaries	-3 628	-48
Total other comprehensive income	49 925	21 189
Total comprehensive income	107 525	79 017
including:
Comprehensive profit attributable to the owners of the parent company	108 527	77 708
Comprehensive profit attributable to non-controlling interests	-1 002	1 309
Basic earnings per share (in euros per share)	2.84	2.75
Diluted earnings per share (in euros per share)	2.78	2.68

CONSOLIDATED STATEMENT OF CASH FLOWS

Cash flows from operating activities
(in thousands of EUR)	9 months 2026	9 months 2025
Profit for the period	57 600	57 828
Adjustments:
Depreciation, amortisation, and impairment of non-current assets	80 851	98 758
Fair value adjustment of equity investment	2 322	-1 940
Change in the value of derivatives	-3 047	-17 413
Other financial income/expenses	-435	-21 797
Calculated interest expenses	33 081	34 800
Profit/loss from non-current assets sold	-1 919	-706
Income from grants recognised as revenue	-531	-1 079
Corporate income tax expense	21 891	17 886
Recognition and adjustment of provisions	3 574	21 237
Income tax paid	-21 601	-17 475
Change in receivables and prepayments related to operating activities	2 271	35 661
Change in inventories	-9 583	57 722
Change in payables and prepayments relating to operating activities	-3 748	-7 995
Change in biological assets	1 302	232
Total cash flows from operating activities	162 028	255 719
Cash flows from investing activities	9 months 2026	9 months 2025
Proceeds from the sale of associates	2 752	0
Net cash flows on acquisition of subsidiaries	-2 725	-39 927
Payments to acquire associates	-1	-1 332
Received dividends	22	0
Repayments of loans granted	182	2 708
Interest received	2 484	2 134
Purchases of investment property	-1 757	-2 116
Payments for purchases of property, plant and equipment and intangible assets	-58 960	-52 605
Proceeds from sale of property	3 217	78 110
Total cash flows used in investing activities	-54 786	-13 028
Cash flows used in financing activities	9 months 2026	9 months 2025
Proceeds from targeted financing	2 644	2 638
Changes in overdraft	-739	-43 513
Proceeds from borrowings	38 031	99 173
Repayments of borrowings	-90 811	-248 146
Repayment of finance lease liabilities	-18 063	-11 703
Interest paid	-32 023	-34 088
Dividends paid	-39 043	-38 511
Repurchase of own shares	-2 286	22
Total cash flows used in financing activities	-142 290	-274 128
TOTAL NET CASH FLOW	-35 048	-31 437
Cash at the beginning of the year	219 771	167 579
Cash at the end of the period	184 723	136 142
Net change in cash	-35 048	-31 437

Infortar operates in seven countries, the company’s main fields of activity are maritime transport, energy and real estate. Infortar owns a 68.38% shareholding in Tallink Grupp, a 100% share in Elenger Grupp and a versatile and modern real estate portfolio of approx. 143,000 m2. In addition to the three main areas of activity, Infortar also operates in construction and mineral resources, agriculture, and other areas. A total of 141 companies belong to the Infortar group, including 3 associates and 2 subsidiaries of associates. Excluding associates, Infortar employs 6203 people.

Additional information:

Kadri Laanvee
Investor Relations Manager
Phone: +372 5156662
e-mail: kadri.laanvee@infortar.ee
www.infortar.ee/en/investor

Attachments

• Q3 report 2026_ENG
• Q3 presentation

Infortar will arrange a webinar for investors today 2 November 2026. Please join the webinar via the following links:

at 12:00 (Tallinn local time) Estonian webinar
at 14:00 (Tallinn local time) English webinar

At the end of September, Infortar’s total assets stood at €2.62 billion and equity at €1.25 billion. The Group’s borrowings decreased by 5.5% compared with the end of the previous year to €1.01 billion, while net debt declined by 2.8% to €828 million. In the third quarter, Infortar generated revenue of €458 million and a net profit of €50 million.

“The third quarter brought key decisions that will shape Infortar’s development in the years ahead and create a platform for further growth. We have consistently expanded our operations in sectors where we see long-term growth potential. In September, we signed an agreement to acquire the Lithuanian agricultural group Litagra at an enterprise value of €95 million. We completed the acquisition in October, making Infortar Agro the largest milk producer in the Baltic states. This marks an important step in the development of our agricultural business and provides a strong foundation for further growth,” said Ain Hanschmidt, Chairman of the Management Board of Infortar.

“Tallink delivered a strong summer quarter, with growth in passenger numbers, cargo volumes and revenue. Despite rising fuel prices and environmental levies, Tallink remains focused on cost efficiency. Elenger focused on ensuring a reliable supply of energy for its customers ahead of the heating season, increasing its gas storage inventories and securing additional LNG deliveries. Our real estate business continued to grow steadily and rental income increased,” Hanschmidt added.

Major Events
Energy

In the third quarter, natural gas consumption in the Baltic-Finnish region totalled 5.6 TWh, decreasing by 6% compared with the previous year (5.9 TWh). Elenger Grupp’s gas and electricity sales volumes in the third quarter decreased by 27% year on year to 2.8 TWh (compared to 3.8 TWh in Q3 2025). The decline was primarily driven by a reduction in wholesale sales. Despite the overall decline in sales volumes, Elenger’s gas market share in the Baltic-Finnish market increased to 31%, and Estonia accounted for 14% of energy sales.

Maritime transport

In the third quarter, Tallink carried 1,816,174 passengers, representing a 2.8% increase year-on-year. The number of cargo units transported increased by 7.8% to 64,980, while the number of passenger vehicles decreased by 1.1% to 249,100.

As at the end of the quarter, Tallink operated 11 vessels including 2 shuttle vessels, 5 passenger vessels, 3 vessels that were chartered out and 1 in lay-up.

Real estate and infrastructure

In Q3 2026, INF Infra, part of the Infortar Group, continued the construction of Rail Baltica’s mainline on the Kangru-Saku section. The contract value is EUR 67.2 million, and the work is planned to continue until March 2028.

In Q3 2026, construction of a Depo DIY Store continued on the property adjacent to the Tallink Tennis Centre. The project is scheduled for completion in the spring of 2027.

In Q3 2026, the reconstruction and expansion project of the Radisti 7 warehouse and office building continued. The works are being carried out by INF Ehitus and are scheduled for completion by the end of 2026.

Key financial figures

Key figures	Q3 2026	Q3 2025	9 months 2026	9 months 2025
Revenue, m€	457.508	467.693	1,403.425	1,419.562
Gross profit, m€	93.849	95.828	207.981	177.564
EBITDA, m€	87.423	104.927	198.651	189.978
EBITDA margin (%)	19.1%	22.4%	14.2%	13.4%
Operating profit (EBIT), m€	66.732	64.836	117.800	91.219
Profit before tax, m€	52.296	73.019	79.491	75.714
Income tax expense, m€	-1.897	-0.780	-21.891	-17.886
Net profit (-loss), m€	50.399	72.239	57.600	57.828
Net profit (-loss) attributable to owners of the parent, m€	43.439	59.068	58.602	56.519
Earnings per share (euros)*	2.11	2.87	2.84	2.75
Total equity, m€	1,248.133	1,207.947	1,248.133	1,207.947
Loan and lease liabilities, m€	1,012.732	1,035.423	1,012.732	1,035.423
Net debt, m€	828.009	899.281	828.009	899.281
Investment loans / EBITDA**	3.0x	3.3x	3.0x	3.3x

_{*Basic earnings per share is calculated by dividing profit attributable to owners of the parent for the period by the weighted average number of ordinary shares outstanding during the same period, excluding own shares.** The investment loans to EBITDA ratio is calculated by dividing long-term investment loans disclosed in Note 7.1 by EBITDA for the trailing twelve months, comprising the first nine months of the reporting year and the fourth quarter of the previous year.}

Revenue

In the first nine months of the 2026 financial year, the Group’s consolidated revenue was EUR 1,403.425 million (9 months 2025: EUR 1,419.562 million).

EBITDA and Segment Reporting

In the first nine months of the 2026 financial year, the maritime transport segment’s EBITDA was EUR 104.025 million (9 months 2025: EUR 102.217 million).

In the first nine months of the 2026 financial year, the energy segment’s EBITDA was EUR 71.476 million (9 months 2025: EUR 76.597 million).

The profitability of the real estate segment is assessed based on the standalone EBITDA of the real estate companies. In the first nine months of the 2026 financial year, real estate EBITDA was EUR 12.034 million (9 months 2025: EUR 10.962 million).

Net Profit (Loss)

In the first nine months of the 2026 financial year, consolidated net profit was EUR 57.600 million, of which EUR 58.602 million was attributable to owners of the parent (9 months 2025: EUR 57.828 million and EUR 56.519 million, respectively).

Investments

In the first nine months of the 2026 financial year, the Group’s total investments amounted to approximately EUR 61 million (9 months 2025: EUR 96 million).

Financing

As at 30 September 2026, loan and lease liabilities totalled EUR 1,012.732 million (31 December 2025: EUR 1,071.353 million).

As at 30 September 2026, the Group’s net debt was EUR 828.009 million (31 December 2025: EUR 851.582 million). The net debt to EBITDA ratio was 3.1 (31 December 2025: 3.7).

Dividends

According to the dividend policy, the objective is to pay dividends of at least 1 euro per share per financial year. Based on Resolution 2.2 of the Annual General Meeting approved on 4 June 2026, a dividend of EUR 3.02 per share will be paid to shareholders for the 2025 financial year. The first payment was made on 15 July 2026, and the second payment will be made on 15 December 2026 with transfer to the shareholders’ bank accounts.

STATEMENT OF FINANCIAL POSITION

(in thousands of EUR)	30.09.26	31.12.25
Current assets
Cash and cash equivalents	184 723	219 771
Derivative financial assets	62 115	4 732
Settled derivative receivables	4 376	1 823
Trade receivables	138 436	153 473
Prepayments for taxes	7 642	5 659
Other receivables and prepayments	45 677	38 878
Prepayments for inventories	1 039	476
Inventories	99 692	90 672
Biological assets	1 471	1 545
Total current assets	545 171	517 029
Non-current assets	30.09.26	31.12.25
Investments in associates	16 339	21 412
Long-term derivative instruments	10 781	1 079
Other non-current receivables	32 892	31 648
Property, plant and equipment at fair value	1 187 384	1 202 173
Investment property	68 629	66 872
Property, plant and equipment	673 344	669 797
Intangible assets	36 864	37 930
Right-of-use assets	41 726	39 645
Biological assets	7 794	9 022
Total non-current assets	2 075 753	2 079 578
TOTAL ASSETS	2 620 924	2 596 607
(in thousands of EUR)	30.09.26	31.12.25
Current liabilities
Loan liabilities	229 556	338 515
Lease liabilities	7 653	10 029
Trade payables	108 555	123 330
Tax liabilities	52 584	44 972
Buyers’ advances	37 053	38 621
Settled derivatives	2 211	4 156
Other current liabilities	79 306	69 677
Short-term derivative instruments	21 411	9 552
Total current liabilities	538 329	638 852
Non-current liabilities	30.09.26	31.12.25
Long-term provisions	6 794	8 695
Deferred tax liabilities	2 183	1 894
Other long-term liabilities	48 399	46 028
Long-term derivatives	1 563	2 925
Loan liabilities	741 627	686 187
Lease liabilities	33 896	36 622
Total non-current liabilities	834 462	782 351
TOTAL LIABILITIES	1 372 791	1 421 203
(in thousands of EUR)	30.09.26	31.12.25
Equity
Share capital	2 117	2 117
Own shares	-3 076	-790
Share premium	32 484	32 484
Reserve capital	212	212
Option reserve	13 663	10 099
Hedging reserve	46 284	-7 260
Unrealised exchange rate differences	-2 461	1 167
Post-employment benefit obligation reserve	-550	-559
Retained earnings	903 763	884 204
Total equity attributable to equity holders of the Parent	992 436	921 674
Non-controlling interests	255 697	253 730
Total equity	1 248 133	1 175 404
TOTAL LIABILITIES AND EQUITY	2 620 924	2 596 607

CONSOLIDATED INCOME STATEMENT

(in thousands of EUR)	Q3 2026	Q3 2025	9 months 2026	9 months 2025
Revenue	457 508	467 693	1 403 425	1 419 562
Cost of goods and services sold	-363 665	-371 837	-1 195 355	-1 241 781
Write-down of receivables	6	-28	-89	-217
Gross profit	93 849	95 828	207 981	177 564
Marketing expenses	-10 458	-11 123	-33 840	-34 218
General administrative expenses	-20 643	-18 804	-65 930	-62 325
Profit (loss) from derivatives	1 291	-1 145	-214	8 037
Profit (loss) from biological assets	2 448	4 511	3 714	4 615
Gain/(loss) from changes in the fair value of non-current assets	0	-5 607	0	-5 607
Other operating income	894	2 237	10 412	6 473
Other operating expenses	-649	-1 061	-4 323	-3 320
Operating profit	66 732	64 836	117 800	91 219
(in thousands of EUR)	Q3 2026	Q3 2025	9 months 2026	9 months 2025
Profit (loss) from investments accounted for using the equity method	292	619	-1 849	1 940
Financial income and expenses:
Income/(expense) from financial investments	-2 365	17 595	-2 583	16 984
Interest expense	-12 050	-10 323	-33 081	-34 800
Interest income	773	609	2 479	2 346
Profit (loss) from changes in exchange rates	-199	388	-1 116	2
Other financial income and expenses	-887	-705	-2 159	-1 977
Total financial income and expenses	-14 728	7 564	-36 460	-17 445
Profit before tax	52 296	73 019	79 491	75 714
Corporate income tax	-1 897	-780	-21 891	-17 886
Profit/(loss) for the period	50 399	72 239	57 600	57 828
including:
Profit attributable to the owners of the parent company	43 439	59 068	58 602	56 519
Profit attributable to non-controlling interests	6 960	13 171	-1 002	1 309

Other comprehensive income	9 months 2026	9 months 2025
Items that will not be reclassified to profit or loss:
Revaluation of post-employment benefit obligations	9	141
Items that may be subsequently reclassified to profit or loss:
Cash flow hedging instruments – effective portion of changes in fair value	53 544	21 096
Exchange rate differences attributable to foreign subsidiaries	-3 628	-48
Total other comprehensive income	49 925	21 189
Total comprehensive income	107 525	79 017
including:
Comprehensive profit attributable to the owners of the parent company	108 527	77 708
Comprehensive profit attributable to non-controlling interests	-1 002	1 309
Basic earnings per share (in euros per share)	2.84	2.75
Diluted earnings per share (in euros per share)	2.78	2.68

CONSOLIDATED STATEMENT OF CASH FLOWS

Cash flows from operating activities
(in thousands of EUR)	9 months 2026	9 months 2025
Profit for the period	57 600	57 828
Adjustments:
Depreciation, amortisation, and impairment of non-current assets	80 851	98 758
Fair value adjustment of equity investment	2 322	-1 940
Change in the value of derivatives	-3 047	-17 413
Other financial income/expenses	-435	-21 797
Calculated interest expenses	33 081	34 800
Profit/loss from non-current assets sold	-1 919	-706
Income from grants recognised as revenue	-531	-1 079
Corporate income tax expense	21 891	17 886
Recognition and adjustment of provisions	3 574	21 237
Income tax paid	-21 601	-17 475
Change in receivables and prepayments related to operating activities	2 271	35 661
Change in inventories	-9 583	57 722
Change in payables and prepayments relating to operating activities	-3 748	-7 995
Change in biological assets	1 302	232
Total cash flows from operating activities	162 028	255 719
Cash flows from investing activities	9 months 2026	9 months 2025
Proceeds from the sale of associates	2 752	0
Net cash flows on acquisition of subsidiaries	-2 725	-39 927
Payments to acquire associates	-1	-1 332
Received dividends	22	0
Repayments of loans granted	182	2 708
Interest received	2 484	2 134
Purchases of investment property	-1 757	-2 116
Payments for purchases of property, plant and equipment and intangible assets	-58 960	-52 605
Proceeds from sale of property	3 217	78 110
Total cash flows used in investing activities	-54 786	-13 028
Cash flows used in financing activities	9 months 2026	9 months 2025
Proceeds from targeted financing	2 644	2 638
Changes in overdraft	-739	-43 513
Proceeds from borrowings	38 031	99 173
Repayments of borrowings	-90 811	-248 146
Repayment of finance lease liabilities	-18 063	-11 703
Interest paid	-32 023	-34 088
Dividends paid	-39 043	-38 511
Repurchase of own shares	-2 286	22
Total cash flows used in financing activities	-142 290	-274 128
TOTAL NET CASH FLOW	-35 048	-31 437
Cash at the beginning of the year	219 771	167 579
Cash at the end of the period	184 723	136 142
Net change in cash	-35 048	-31 437

Infortar operates in seven countries, the company’s main fields of activity are maritime transport, energy and real estate. Infortar owns a 68.38% shareholding in Tallink Grupp, a 100% share in Elenger Grupp and a versatile and modern real estate portfolio of approx. 143,000 m2. In addition to the three main areas of activity, Infortar also operates in construction and mineral resources, agriculture, and other areas. A total of 141 companies belong to the Infortar group, including 3 associates and 2 subsidiaries of associates. Excluding associates, Infortar employs 6203 people.

Additional information:

Kadri Laanvee
Investor Relations Manager
Phone: +372 5156662
e-mail: kadri.laanvee@infortar.ee
www.infortar.ee/en/investor

Attachments

• Q3 report 2026_ENG
• Q3 presentation

Luxembourg – 2 November 2026 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a substantial¹ contract by Aker BP for the Lyra field development project, formerly known as Kjøttkake, located in the northern part of the North Sea, approximately 44 kilometres from the Gjøa platform offshore Norway.

The Lyra field development will be tied back to the existing Gjøa platform through the NOVA field infrastructure.

Subsea7’s scope includes engineering, procurement, construction and installation (EPCI) of gas lift and production pipelines and associated subsea infrastructure. The production pipeline will feature a pipe-in-pipe design and offshore installation activities will be executed using vessels from Subsea7’s fleet.

Project management and engineering activities will commence immediately at Subsea7’s office in Stavanger, Norway. Pipeline fabrication will take place at Subsea7’s spool base at Vigra, Norway. Offshore operations are scheduled for execution during 2026, 2027 and 2028.

Lyra is a fast-track development targeting first oil in 2028, only three years after discovery. To enable the accelerated schedule, Subsea7 received a pre-commitment for critical long-lead items in December 2025.

Erik Femsteinevik, Vice President Norway at Subsea7, said: “Lyra showcases the strength of the Aker BP Subsea Alliance². From securing long-lead items to mobilising engineering, fabrication and offshore resources, this award demonstrates Subsea7’s ability to deliver first production at exceptional speed. We are excited to support Aker BP on another landmark development and proud to bring the expertise of our Stavanger and Vigra teams to a project that will deliver significant value for our client, partners and the Norwegian Continental Shelf.”

1. Subsea7 defines a substantial contract as being between $150 million and $300 million.
2. The Aker BP Subsea Alliance is a partnership between Aker BP, Subsea7 and OneSubsea.

*******************************************************************************

Subsea7 is a global leader in the delivery of offshore projects and services for the evolving energy industry, creating sustainable value by being the industry’s partner and employer of choice in delivering the efficient offshore solutions the world needs.

Subsea7 is listed on the Oslo Børs (SUBC), ISIN LU0075646355, LEI 222100AIF0CBCY80AH62.

*******************************************************************************

Contact for investment community enquiries:
Katherine Tonks
Investor Relations Director
Tel +44 20 8210 5568
ir@subsea7.com

Contact for media enquiries:
Jan Roger Moksnes
Communications Manager
Tel +47 41515777
janroger.moksnes@subsea7.com
www.subsea7.com

Forward-Looking Statements: This document may contain ‘forward-looking statements’ (within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995). These statements relate to our current expectations, beliefs, intentions, assumptions or strategies regarding the future and are subject to known and unknown risks that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements may be identified by the use of words such as ‘anticipate’, ‘believe’, ‘estimate’, ‘expect’, ‘future’, ‘goal’, ‘intend’, ‘likely’ ‘may’, ‘plan’, ‘project’, ‘seek’, ‘should’, ‘strategy’ ‘will’, and similar expressions. The principal risks which could affect future operations of the Group are described in the ‘Risk Management’ section of the Group’s Annual Report and Consolidated Financial Statements. Factors that may cause actual and future results and trends to differ materially from our forward-looking statements include (but are not limited to): (i) our ability to deliver fixed price projects in accordance with client expectations and within the parameters of our bids, and to avoid cost overruns; (ii) our ability to collect receivables, negotiate variation orders and collect the related revenue; (iii) our ability to recover costs on significant projects; (iv) capital expenditure by oil and gas companies, which is affected by fluctuations in the price of, and demand for, crude oil and natural gas; (v) unanticipated delays or cancellation of projects included in our backlog; (vi) competition and price fluctuations in the markets and businesses in which we operate; (vii) the loss of, or deterioration in our relationship with, any significant clients; (viii) the outcome of legal proceedings or governmental inquiries; (ix) uncertainties inherent in operating internationally, including economic, political and social instability, boycotts or embargoes, labour unrest, changes in foreign governmental regulations, corruption and currency fluctuations; (x) the effects of a pandemic or epidemic or a natural disaster; (xi) liability to third parties for the failure of our joint venture partners to fulfil their obligations; (xii) changes in, or our failure to comply with, applicable laws and regulations (including regulatory measures addressing climate change); (xiii) operating hazards, including spills, environmental damage, personal or property damage and business interruptions caused by adverse weather; (xiv) equipment or mechanical failures, which could increase costs, impair revenue and result in penalties for failure to meet project completion requirements; (xv) the timely delivery of vessels on order and the timely completion of ship conversion programmes; (xvi) our ability to keep pace with technological changes and the impact of potential information technology, cyber security or data security breaches; (xvii) global availability at scale and commercially viability of suitable alternative vessel fuels; and (xviii) the effectiveness of our disclosure controls and procedures and internal control over financial reporting. Many of these factors are beyond our ability to control or predict. Given these uncertainties, you should not place undue reliance on the forward-looking statements. Each forward-looking statement speaks only as of the date of this document. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. 
This stock exchange release was published by Katherine Tonks, Investor Relations, Subsea7, on 08:00 CET on 2 November 2026

Attachment

• SUBC Lyra

Luxembourg – 2 November 2026 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a substantial¹ contract by Aker BP for the Lyra field development project, formerly known as Kjøttkake, located in the northern part of the North Sea, approximately 44 kilometres from the Gjøa platform offshore Norway.

The Lyra field development will be tied back to the existing Gjøa platform through the NOVA field infrastructure.

Subsea7’s scope includes engineering, procurement, construction and installation (EPCI) of gas lift and production pipelines and associated subsea infrastructure. The production pipeline will feature a pipe-in-pipe design and offshore installation activities will be executed using vessels from Subsea7’s fleet.

Project management and engineering activities will commence immediately at Subsea7’s office in Stavanger, Norway. Pipeline fabrication will take place at Subsea7’s spool base at Vigra, Norway. Offshore operations are scheduled for execution during 2026, 2027 and 2028.

Lyra is a fast-track development targeting first oil in 2028, only three years after discovery. To enable the accelerated schedule, Subsea7 received a pre-commitment for critical long-lead items in December 2025.

Erik Femsteinevik, Vice President Norway at Subsea7, said: “Lyra showcases the strength of the Aker BP Subsea Alliance². From securing long-lead items to mobilising engineering, fabrication and offshore resources, this award demonstrates Subsea7’s ability to deliver first production at exceptional speed. We are excited to support Aker BP on another landmark development and proud to bring the expertise of our Stavanger and Vigra teams to a project that will deliver significant value for our client, partners and the Norwegian Continental Shelf.”

1. Subsea7 defines a substantial contract as being between $150 million and $300 million.
2. The Aker BP Subsea Alliance is a partnership between Aker BP, Subsea7 and OneSubsea.

*******************************************************************************

Subsea7 is a global leader in the delivery of offshore projects and services for the evolving energy industry, creating sustainable value by being the industry’s partner and employer of choice in delivering the efficient offshore solutions the world needs.

Subsea7 is listed on the Oslo Børs (SUBC), ISIN LU0075646355, LEI 222100AIF0CBCY80AH62.

*******************************************************************************

Contact for investment community enquiries:
Katherine Tonks
Investor Relations Director
Tel +44 20 8210 5568
ir@subsea7.com

Contact for media enquiries:
Jan Roger Moksnes
Communications Manager
Tel +47 41515777
janroger.moksnes@subsea7.com
www.subsea7.com

Forward-Looking Statements: This document may contain ‘forward-looking statements’ (within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995). These statements relate to our current expectations, beliefs, intentions, assumptions or strategies regarding the future and are subject to known and unknown risks that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements may be identified by the use of words such as ‘anticipate’, ‘believe’, ‘estimate’, ‘expect’, ‘future’, ‘goal’, ‘intend’, ‘likely’ ‘may’, ‘plan’, ‘project’, ‘seek’, ‘should’, ‘strategy’ ‘will’, and similar expressions. The principal risks which could affect future operations of the Group are described in the ‘Risk Management’ section of the Group’s Annual Report and Consolidated Financial Statements. Factors that may cause actual and future results and trends to differ materially from our forward-looking statements include (but are not limited to): (i) our ability to deliver fixed price projects in accordance with client expectations and within the parameters of our bids, and to avoid cost overruns; (ii) our ability to collect receivables, negotiate variation orders and collect the related revenue; (iii) our ability to recover costs on significant projects; (iv) capital expenditure by oil and gas companies, which is affected by fluctuations in the price of, and demand for, crude oil and natural gas; (v) unanticipated delays or cancellation of projects included in our backlog; (vi) competition and price fluctuations in the markets and businesses in which we operate; (vii) the loss of, or deterioration in our relationship with, any significant clients; (viii) the outcome of legal proceedings or governmental inquiries; (ix) uncertainties inherent in operating internationally, including economic, political and social instability, boycotts or embargoes, labour unrest, changes in foreign governmental regulations, corruption and currency fluctuations; (x) the effects of a pandemic or epidemic or a natural disaster; (xi) liability to third parties for the failure of our joint venture partners to fulfil their obligations; (xii) changes in, or our failure to comply with, applicable laws and regulations (including regulatory measures addressing climate change); (xiii) operating hazards, including spills, environmental damage, personal or property damage and business interruptions caused by adverse weather; (xiv) equipment or mechanical failures, which could increase costs, impair revenue and result in penalties for failure to meet project completion requirements; (xv) the timely delivery of vessels on order and the timely completion of ship conversion programmes; (xvi) our ability to keep pace with technological changes and the impact of potential information technology, cyber security or data security breaches; (xvii) global availability at scale and commercially viability of suitable alternative vessel fuels; and (xviii) the effectiveness of our disclosure controls and procedures and internal control over financial reporting. Many of these factors are beyond our ability to control or predict. Given these uncertainties, you should not place undue reliance on the forward-looking statements. Each forward-looking statement speaks only as of the date of this document. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. 
This stock exchange release was published by Katherine Tonks, Investor Relations, Subsea7, on 08:00 CET on 2 November 2026

Attachment

• SUBC Lyra

ENDEAVOUR REPORTS ACCESS RAMP SUBSIDENCE AT THE MANA MINE

London, 2 November 2026 – Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) (“Endeavour” or the “Company”) reports that on 28 October the access ramp leading to the depleted Wona open pit partially subsided, restricting access to the Dangouna and Aviera underground portals at the Mana mine in Burkina Faso.

No one was harmed during the incident, and emergency protocols were initiated immediately, which included the evacuation of all underground workers and the notification of the local authorities in Burkina Faso.

Underground mining activities at all three active underground portals at Mana have been suspended to allow for detailed geotechnical analysis and ramp remediation work to be assessed.

Endeavour remains on track to achieve its FY-2026 Group production and AISC guidance. Furthermore, the company is actively evaluating options to mitigate the impact of the incident on Mana’s production, including the restart and acceleration of mining activities in the Wona portal, which remains accessible, and other near-mine open pits.

An update on the ongoing geotechnical analysis and details on the remediation plan will be provided within Q3-2026 financial results, on 12 November 2026.

CONTACT INFORMATION

For Investor Relations Enquiries:	For Media Enquiries:
Jack Garman	Brunswick Group LLP in London
Vice President of Investor Relations	Carole Cable, Partner
+44 203 011 2723	+ 44 207 404 5959
investor@endeavourmining.com	ccable@brunswickgroup.com

ABOUT ENDEAVOUR MINING PLC

Endeavour Mining is one of the world’s senior gold producers and the largest in West Africa, with operating assets across Senegal, Cote d’Ivoire and Burkina Faso and a strong portfolio of advanced development projects and exploration assets.

A member of the World Gold Council, Endeavour is committed to the principles of responsible mining and delivering sustainable value to its employees, stakeholders and the communities where it operates. Endeavour is admitted to listing and to trading on the London Stock Exchange and the Toronto Stock Exchange, under the symbol EDV.

For more information, please visit www.endeavourmining.com.

Attachment

• 261102 – NR – Mana Ramp Subsidence

ENDEAVOUR REPORTS ACCESS RAMP SUBSIDENCE AT THE MANA MINE

London, 2 November 2026 – Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) (“Endeavour” or the “Company”) reports that on 28 October the access ramp leading to the depleted Wona open pit partially subsided, restricting access to the Dangouna and Aviera underground portals at the Mana mine in Burkina Faso.

No one was harmed during the incident, and emergency protocols were initiated immediately, which included the evacuation of all underground workers and the notification of the local authorities in Burkina Faso.

Underground mining activities at all three active underground portals at Mana have been suspended to allow for detailed geotechnical analysis and ramp remediation work to be assessed.

Endeavour remains on track to achieve its FY-2026 Group production and AISC guidance. Furthermore, the company is actively evaluating options to mitigate the impact of the incident on Mana’s production, including the restart and acceleration of mining activities in the Wona portal, which remains accessible, and other near-mine open pits.

An update on the ongoing geotechnical analysis and details on the remediation plan will be provided within Q3-2026 financial results, on 12 November 2026.

CONTACT INFORMATION

For Investor Relations Enquiries:	For Media Enquiries:
Jack Garman	Brunswick Group LLP in London
Vice President of Investor Relations	Carole Cable, Partner
+44 203 011 2723	+ 44 207 404 5959
investor@endeavourmining.com	ccable@brunswickgroup.com

ABOUT ENDEAVOUR MINING PLC

Endeavour Mining is one of the world’s senior gold producers and the largest in West Africa, with operating assets across Senegal, Cote d’Ivoire and Burkina Faso and a strong portfolio of advanced development projects and exploration assets.

A member of the World Gold Council, Endeavour is committed to the principles of responsible mining and delivering sustainable value to its employees, stakeholders and the communities where it operates. Endeavour is admitted to listing and to trading on the London Stock Exchange and the Toronto Stock Exchange, under the symbol EDV.

For more information, please visit www.endeavourmining.com.

Attachment

• 261102 – NR – Mana Ramp Subsidence